🇺🇸 FDA

Intelligence · Clinical Pipeline

Tonix Pharmaceuticals Holding Pipeline

All ClinicalTrials.gov programs at Tonix Pharmaceuticals Holding — phase, modality, and trial IDs.

Programs
30

Quick answer

Tonix Pharmaceuticals Holding has 30 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  2. TNX-102 SL

    Tonix Pharmaceuticals Holding

    PTSD

    phase 3 small molecule terminated

    6 trials

  3. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule completed

    2 trials

  4. TNX-102 SL 2.8mg

    Tonix Pharmaceuticals Holding

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  5. TNX-102 SL 5.6 mg

    Tonix Pharmaceuticals Holding

    PTSD

    phase 3 small molecule completed

    1 trial

  6. TNX-102 SL Tablet 2.8 mg

    Tonix Pharmaceuticals Holding

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  7. TNX-102 SL Tablet, 2.8 mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule terminated

    1 trial

  8. TNX-102 SL Tablet, 2.8mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

  9. TNX-102 SL Tablet, 5.6 mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

  10. Cyclobenzaprine HCl

    Tonix Pharmaceuticals Holding

    Acute Stress Reaction

    phase 2 small molecule active

    1 trial

  11. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

    phase 2 small molecule completed

    1 trial

  12. TNX-1300

    Tonix Pharmaceuticals Holding

    Cocaine Intoxication

    phase 2 small molecule terminated

    1 trial

  13. TNX-1500

    Tonix Pharmaceuticals Holding

    Kidney Transplant

    phase 2 small molecule active

    1 trial

  14. TNX-1900

    Tonix Pharmaceuticals Holding

    Chronic Migraine

    phase 2 small molecule completed

    1 trial

  15. TNX-201

    Tonix Pharmaceuticals Holding

    Tension-Type Headache

    phase 2 small molecule completed

    1 trial

  16. TNX-601 ER

    Tonix Pharmaceuticals Holding

    Depression

    phase 2 small molecule completed

    1 trial

  17. Imaging procedure to measure the distribution of a newly developed radiolabeled ligand for the oxytocin receptor

    Tonix Pharmaceuticals Holding

    Pain, Face

    phase 1 small molecule completed

    1 trial

  18. Intranasal Oxytocin (IN-OXT)

    Tonix Pharmaceuticals Holding

    Vasopressin Deficiency

    phase 1 small molecule active

    1 trial

  19. SL TNX-102 2.4 mg at pH 3.5

    Tonix Pharmaceuticals Holding

    Healthy Adults

    phase 1 small molecule completed

    1 trial

  20. SL TNX-102 at 2.4 mg

    Tonix Pharmaceuticals Holding

    Healthy Adults

    phase 1 small molecule completed

    1 trial

  21. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Healthy Subjects (HS)

    phase 1 small molecule completed

    1 trial

  22. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  23. TNX-102 SL 5.6 mg

    Tonix Pharmaceuticals Holding

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  24. TNX-102 SL Tablet

    Tonix Pharmaceuticals Holding

    Pharmakokinetic

    phase 1 small molecule active

    1 trial

  25. TNX-102 SL Tablets at 2.8 mg

    Tonix Pharmaceuticals Holding

    Healthy Adults

    phase 1 small molecule completed

    1 trial

  26. TNX-1500

    Tonix Pharmaceuticals Holding

    Phase 1 First-in-human Study Involving Healthy Subjects

    phase 1 small molecule completed

    1 trial

  27. TNX-201 35 mg

    Tonix Pharmaceuticals Holding

    Healthy

    phase 1 small molecule completed

    1 trial

  28. TNX-2110

    Tonix Pharmaceuticals Holding

    Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2

    phase 1 mab terminated

    1 trial

  29. Treatment A

    Tonix Pharmaceuticals Holding

    Healthy

    phase 1 small molecule completed

    1 trial

  30. Treatment A

    Tonix Pharmaceuticals Holding

    Healthy Adults

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Tonix Pharmaceuticals Holding have?

30 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.